Status:
COMPLETED
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer
Lead Sponsor:
Tanta University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE3
Brief Summary
Investigation of the possible efficacy and safety of lansoprazole co-administration with neoadjuvant chemotherapy in tumor response in women with breast cancer who will be planned for surgery.
Detailed Description
Several studies revealed that PPIs inhibit not only the H+/K+ ATPase in gastric parietal cells, but also the vacuolar H+ ATPase (V-ATPase) overexpressed in tumor cells, the V-ATPase is an ATP-dependen...
Eligibility Criteria
Inclusion
- Females with age ≥ 18 years old.
- Newly diagnosed breast cancer patients.
- Planned neoadjuvant chemotherapy.
Exclusion
- Pregnancy.
- Nursing mothers.
- Active or uncontrolled infection.
- Presence of another malignancies.
- Inadequate blood picture.
- Serum Creatinine more than 1.5 mg /dl.
- AST and ALT more than 2.5 upper limit.
- History of known hypersensitivity to lansoprazole.
Key Trial Info
Start Date :
June 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 5 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04874935
Start Date
June 10 2021
End Date
November 5 2022
Last Update
November 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy
Tanta, Egypt, 32511